Plus   Neg

Novavax, Serum Institute Of India Boost COVID-19 Vaccine Manufacturing Agreement To 2 Bln/year

Biotechnology company Novavax Inc. (NVAX) announced Tuesday an amendment to its existing agreement with Serum Institute of India Pvt. Ltd. or SIIPL, under which SIIPL will also manufacture the antigen component of NVX-CoV2373, Novavax' COVID-19 vaccine candidate.

With this agreement, Novavax increases its global manufacturing capacity of NVX-CoV2373 to over two billion doses annually, when all planned capacity has been brought online by mid-2021. The agreement expands Novavax partnership with world's largest vaccine developer to increase global delivery of NVX-CoV2373.

NVX-CoV2373 is a stable, prefusion protein made using Novavax' recombinant protein nanoparticle technology and includes Novavax' proprietary Matrix-M adjuvant.

Novavax said it will continue to work with extraordinary urgency to develop the vaccine, now in Phase 2 clinical trials, and anticipates starting Phase 3 efficacy trials around the world in the coming weeks.

The antigen component of NVX-CoV2373 is being manufactured at Novavax CZ in Bohumil, Czech Republic (formerly Praha Vaccines), as well as other partner manufacturing sites in Spain, the U.S., the U.K., Republic of Korea , Japan and India.

Novavax' Matrix-M adjuvant is now being manufactured at Novavax AB in Uppsala, Sweden as well as other partner manufacturing sites in the U.S., Denmark.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission or FTC has launched a new fraud reporting platform, using which, consumers can easily report fraud and all other consumer issues directly to the regulator. In a statement, the FTC said its new website, ReportFraud.ftc.gov, will provide a streamlined and user-friendly way to submit reports about scams, frauds, and bad business practices. Shares of Daimler AG were gaining around 2 percent in the morning trading in Germany after the auto giant reported Friday higher profit in its third-quarter, despite weakness in revenues and sales volume. Further, the company now expects Group EBIT for full year 2020 at the prior-year level, compared to previous expectation of a decline. Retailer Bed Bath & Beyond Inc. is recalling SALT Lounge Chairs citing fall risks, the U.S. Consumer Product Safety Commission announced. The recall involves about 10,000 units sold in the United States and about 330 sold in Canada. The chairs were manufactured in China, and imported by Liberty Procurement Co. Inc., an affiliate of Bed Bath & Beyond.
Follow RTT